rAAV Vector COX20 Gene Replacement for Nervous System Deficiency

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There are currently no treatment options for COX20 deficiency, a rare autosomal recessive neurologic disease affecting children with symptoms such as early onset hypotonia, ataxia, areflexia, dystonia, and sensory neuronopathy, primarily impacting the peripheral nervous system.

Innovation Solution

A gene replacement therapy using recombinant adeno-associated virus (rAAV) vectors encoding the Cytochrome C Oxidase Assembly Factor COX20 protein, delivered via systemic or direct CNS injection, to restore COX20 expression and function in the nervous system.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If gene replacement therapy using rAAV vectors is used to restore COX20 expression, then disease symptoms are alleviated and lactate levels are reduced, but the complexity of the treatment protocol increases

Engineering Contradiction:

Improvedisease symptom alleviationVSAvoidtreatment protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs rAAV vectors as intermediary carriers to deliver the COX20 transgene to target cells in the nervous system. The vector system mediates between the therapeutic gene and the host cells, enabling gene replacement therapy to restore COX20 expression and alleviate disease symptoms through a controlled delivery mechanism

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If COX20 deficiency is treated with gene replacement therapy, then functional COX20 expression is restored, but the risk of viral vector-related adverse effects increases

Engineering Contradiction:

Improvefunctional protein restorationVSAvoidviral vector adverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent utilizes self-complementary AAV vectors that express the transgene and then clear from the system, avoiding persistent viral presence. The vector serves its purpose of delivering the COX20 gene, then is degraded, minimizing long-term viral-related risks while achieving functional protein restoration

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent employs capsid engineering to modify the AAV vector properties, specifically using AAVrh10 capsid proteins with altered binding characteristics to enhance neuronal targeting while reducing off-target effects. This parameter change in vector properties optimizes the balance between therapeutic efficacy and safety

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If tissue-specific promoters are used to drive COX20 expression, then expression specificity to nervous system is improved, but the complexity of vector construction increases

Engineering Contradiction:

Improvetissue-specific expressionVSAvoidvector construction complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent incorporates tissue-specific promoters (such as synapsin promoter) that are active specifically in neuronal tissues, ensuring that COX20 expression occurs only where needed in the nervous system. This local quality control minimizes off-target effects while maintaining therapeutic efficacy in the intended tissue

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20250319209A1Raav vector for the treatment of cox20 deficiency

Publication Date: 2025.10.16 UNIV OF MASSACHUSETTS

AI summary

Aspects of the disclosure provide compositions and methods for promoting expression of functional COX20 protein in a subject. In some embodiments, the disclosure provides methods of treating a subject having COX20 deficiency.